OPINION Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer
INTRODUCTION
Recent advances in systemic therapy have altered the landscape of metastatic prostate cancer. New paradigms of therapy have emerged and as a result, the natural history of prostate cancer is undergoing rapid transformation. Multiple agents with very distinct mechanisms of actions and unique toxicities and efficacies have made the field particularly overwhelming. A lot of these changes have also occurred in a very short time interval of the last 3-5 years. Even the multiple reviews written in the last few years are rapidly outdated as more trials get reported. The focus of this review is to give a summary of the current clinical perspectives of the indications, including pros and cons of the currently approved regimens.
Androgen deprivation therapy remains the mainstay of front-line therapy for advanced prostate cancer. Nevertheless, this treatment is not curative and patients invariably develop progressive disease. Castrate-resistant prostate cancer (CRPC) implies any disease progression (PSA only progression, or progression of existing metastases, or development of new metastasis) despite being on adequate androgen deprivation therapy. The field of advanced prostate cancer, especially in the castrate resistant setting, has undergone a rapid overhaul in the last 5 years. A paradigm shift has occurred, with the availability of multiple novel agents addressing distinct pathways, and demonstrating greater efficacy, in a disease state that previously had a large unmet need.
The judicious use of multiple available agents, with finesse of sequencing, and concomitant palliative care, has prolonged overall survival (OS) and made living with metastatic CRPC a more reasonable and tolerable experience than previously. The expertise of multiple specialties can ensure an optimal outcome, not only in terms of improving life expectancy but helping to lead a full productive life. To deliver the variety of treatments ranging from immunotherapy to bone-targeted radiation therapy, it is imperative to involve multiple specialties in the care of the advanced prostate cancer patient. In addition, the psychological reassurance to patients and families of having continued help and support available from multiple specialties can never be underestimated.
At present, the choice of therapies is predominantly based on clinical prognostic markers, such as patient and tumor characteristics. Development of predictive markers is a dire need in this disease. This will help optimize therapies, reduce unnecessary toxicities and reduce costs. Overcoming resistance to currently available therapies is an area of active research. Identification of novel targets of attack, and agents directed toward these targets, represents ongoing avenues of investigation.
THERAPEUTIC OPTIONS IN UNTREATED METASTATIC PROSTATE CANCER
Conventional androgen suppression therapy remains the mainstay of systemic front-line therapies in metastatic prostate cancer. In metastatic prostate cancer, orchiectomy has gradually been replaced by chemical castration methods with luteinizing hormone releasing hormone (LHRH) analogues or LHRH antagonists. Interestingly, although the addition of antiandrogens to orchiectomy did not seem to add any benefit, combined androgen blockade (addition of antiandrogen) remains superior to LHRH analogue therapy alone [1, 2] .
The results of the Southwest Oncology Group trial 9346 [3 && ] were reported in early 2013. The study randomized metastatic prostate cancer patients to receive either continuous or intermittent androgen suppression therapy. Of the 3040 patients enrolled, 1535 patients (50.4%) were randomized to either continuous (759) or intermittent therapy (770). The hazard ratio of 1.1 (90% confidence interval 0.99, 1.23) revealed that intermittent therapy was not considered non-inferior to continuous androgen deprivation therapy. Median survival was 5.8 years and 5.1 years in the continuous and intermittent arms, respectively. Median OS of extensive disease patients in the intermittent arm was 4.9 years compared with 4.4 years in the continuous arm [hazard ratio (HR): 1.02; 95% CI (0.85, 1.22)]. Median OS of minimal disease patients treated intermittently was 5.4 years as compared with 6.9 years for continuously treated patients [HR: 1.19, 95% CI (0.98, 1.43)]. A total of 1505 patients who were not randomized because of an inability to achieve a nadir PSA of four or less demonstrated a poor clinical outcome with median survival of 1.7 years.
The recently reported results of ECOG 3805 (CHAARTED) [(http://centerformenshealth.com/ center-4-mens-health/new-treatment-now-availablethat-extends-life-in-men-with-highly-advanced-pro state-cancer) the study results of ECOG 3805 demonstrating OS benefit with early docetaxel chemotherapy may change standard of care in patients with extensive disease metastatic prostate cancer] are likely to drastically change our therapeutic sequencing in metastatic prostate cancer. The study evaluated the OS benefit of adding docetaxel-based chemotherapy to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. The study randomized 790 men with metastatic prostate cancer to receive androgen deprivation therapy AE six cycles of docetaxel chemotherapy. A recent interim analysis of the study revealed that the addition of chemotherapy improved survival outcome, with 3-year OS of 69% with the combination, and 52.5% with androgen deprivation therapy. Men with extensively metastatic disease (four or more sites of bone metastases or the presence of liver metastases) were the most likely to benefit from the addition of chemotherapy. The results of this randomized trial will lead us to consider early use of systemic therapies to improve life expectancy. A
KEY POINTS
Multifaceted therapeutic paradigms have emerged as new standards in advanced CRPC. Level 1 evidence from a randomized trial (ECOG 3805) suggests that early consideration of docetaxelbased chemotherapy in castration-sensitive metastatic disease is indicated.
In addition to chemotherapy, hormone and immune therapies have demonstrated efficacy and present better tolerated systemic therapy options.
Novel targets and agents continue to be evaluated in this incurable disease, which generally has a terminal prognosis.
number of other effective therapies are now being tested in the hormone-sensitive metastatic setting. SWOG 1216 is a randomized trial of androgen deprivation AE TAK-700 in metastatic hormone-sensitive prostate cancer. A multicenter phase II randomized trial is being activated shortly of LHRH analogue þ bicalutamide vs. LHRH analogue þ enzalutamide in metastatic hormone-sensitive prostate cancer.
THERAPY OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
There are multiple therapeutic options available at every juncture of metastatic prostate cancer. At present, all therapies are only approved for CRPC with obvious/radiologic metastatic disease. To date, no systemic therapy has demonstrated benefit, or received FDA approval, in the setting of nonmetastatic CRPC. The clinical parameters commonly used to determine therapeutic choice are eligibility for chemotherapy and extent of disease-related symptoms. Figure 1 illustrates the clinical therapeutic decision-making based on current evidence.
Front-line therapies in castrate-resistant prostate cancer
Historically, mitoxantrone and steroid combination was the first systemic regimen to demonstrate palliative benefit in metastatic CRPC [4, 5] . Despite the lack of survival benefit, this chemotherapy was adopted in the hope of achieving control of diseaserelated morbidities. In 2005, a docetaxel and prednisone regimen, and a combination of estramustine and docetaxel, each demonstrated OS benefit over mitoxantrone and prednisone in independent randomized trials [6, 7] . In addition to the OS benefit provided by docetaxel and prednisone, better supportive care and effective antiemetic therapies have made the delivery of chemotherapy easier. The acceptance of chemotherapy in advanced CRPC is gradually expanding, and the pendulum is shifting toward earlier therapy. This phenomenon probably resulted in the large difference in OS observed in the mitoxantrone and prednisone control arms between the Kantoff and TAX327 trials (median OS 12.3 months in the study reported by Kantoff et al. and 16.5 months in the TAX 327 trial).
The contemporary trials highlight the outcome differences that have partly resulted from earlier therapy and better supportive care. Both abiraterone and enzalutamide [8 & ,9 & ] have resulted in a markedly improved radiologic progression-free survival (PFS), and a trend toward OS benefit in untreated metastatic CRPC (Table 1) ]. Both these agents attack the androgen-receptor interaction pathway, and demonstrate robust efficacy in advanced prostate cancer. Abiraterone is a CYP-17 inhibitor that suppresses adrenal and tumor microenvironment androgen production, and enzalutamide is a competitive antagonist of the androgen receptor. In a placebo controlled double blind randomized trial, 1088 asymptomatic/minimally symptomatic metastatic CRPC patients were treated with prednisone 5 mg twice daily with or without abiraterone 1000 mg orally daily. Abiraterone therapy doubled the median radiologic PFS to 16.5 months as compared with 8.3 months for patients treated with prednisone alone. OS also improved with hazard ratio of 0.75 (95% CI, 0.61-0.93, P ¼ 0.01) leading to the Food and Drug Administration (FDA) approval of abiraterone in the prechemotherapy setting of metastatic CRPC [8 & ]. In October 2013, the results of a similar trial comparing enzalutamide vs. placebo were released. The study, consisting of 1715 randomized patients, was halted early by the independent data and safety reporting committee. Enzalutamide therapy resulted in a 30% reduction in the risk of death, (HR ¼ 0.70, P < 0.0001) and 81% reduction in the risk of radiographic progression (HR ¼ 0.19, P < 0.0001). Treatment with enzalutamide resulted in a calculated point estimate for median OS of 32.4 months (95% CI, 31.5 monthsupper limit not yet reached) vs. 30.2 months (95% CI, 28.0 months-upper limit not yet reached) for patients receiving placebo [9 & ]. The promising results and favorable toxicity profiles of both abiraterone and enzalutamide make a strong clinical case for considering either of these medications in the front-line treatment of metastatic CRPC. However, the improved outcomes noted above can also be attributed to the stringent patient selection criteria required on both the trials discussed above. The eligibility consisted of asymptomatic to minimally symptomatic patients, with good performance status. It is noteworthy that this patient population even with metastatic CRPC was able to stay on therapy with prednisone alone for a median duration of 8.3 months. Chemotherapy would likely have a similar OS outcome, but with an increased risk of toxicities. It is likely that henceforth the initial therapy of metastatic CRPC is likely to be either enzalutamide, or the combination of abiraterone and prednisone. Clinical trials of sequencing and combinations, with assessment of predictive biomarkers, will help determine therapeutic choices in the future. Skeletal morbidity has decreased in incidence, and delayed in occurrence, because of bonetargeted therapies such as zoledronic acid and denosumab [16, 17] . In the future, as more and more effective treatments are developed, the impact of bone-targeted therapies is likely to become more blunted. Immunotherapy with sipuleucel T [13, 14] has demonstrated OS benefit in patients with asymptomatic/minimally symptomatic metastatic CRPC. Clinical, PSA, or symptom responses are not detected or expected with the therapy and hence patient selection is critical. Studies are ongoing to evaluate biomarkers for patient selection and response assessment. The evidence-driven therapeutic sequence in a carefully selected, asymptomatic, slowly progressing, metastatic CRPC patient would be that of sipuleucel T followed by either abiraterone þ prednisone, or enzalutamide ( Fig. 1) .
Combinations of the currently available agents are in clinical trial testing. The Alliance trial of abiraterone AE enzalutamide in metastatic CRPC will be launched shortly. Numerous trials of combinations with docetaxel have been unsuccessful in demonstrating any OS benefit [18] [19] [20] [21] [22] [23] . Vascular endothelial growth factor (VEGF)-targeted therapies, such as with either bevacizumab or aflibercept [18, 19] , when combined with docetaxel, was associated with greater toxicity and no improvement in survival. Multiple other combinations were tested with either no clinical benefit or even an inferior outcome. These include combinations with GVAX (prostate cancer vaccine), DN-101 (high dose calcitriol), atrasentan (endothelin receptor antagonist), dasatinib and lenalidomide [20] [21] [22] [23] (http://www. news-medical.net/news/20121012/Lenalidomideworsens-survival-adverse-events-in-prostate-cancer. aspx).
Second-line therapies
Treatment strategies can be broadly categorized as chemotherapy, hormonal therapy, immunotherapy and radiation therapy. Table 1 summarizes the FDA-approved agents that have demonstrated survival advantage in advanced CRPC. Abiraterone, cabazitaxel and enzalutamide revealed OS benefit in the post-docetaxel chemotherapy setting in randomized trials [10, 11, 12 && ]. The median OS of the different control arms in each of these trials (prednisone, mitoxantrone chemotherapy, and placebo therapies) was similar (10.9, 12.7 and 13.6 months, respectively). The relative OS benefit observed with each of these agents [abiraterone (median survival 14.8 months), cabazitaxel (median survival 15.1 months), and enzalutamide (median survival 18.4 months)], as compared with the control arms was also similar. Hence, the decision about which agent to use post-docetaxel is based on the toxicity profiles of each of the agents, and patient comorbidities. The studies overlapped significantly in that they were conducted in similar patient populations, that is in patients pretreated with docetaxel chemotherapy. This results in a paucity of data in a patient population that has been pretreated with docetaxel and either abiraterone or enzalutamide. Future trials in the third-line setting will be informative in assessing likelihood of response in a CRPC patient population treated with docetaxel and either enzalutamide or abiraterone.
Radium-223 dichloride (alpharadin), an a emitter, selectively targets bone metastases with a particles of radiation. Radium-223 [15 && ] was evaluated in a double blind placebo controlled trial in a patient population that was symptomatic from prostate cancer, and either pretreated (30%) or ineligible to receive chemotherapy. Patients were randomized in a 2 : 1 ratio to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matched placebo. The primary end point of OS favored the use of radium-223 with a hazard ratio of 0.70 and median OS of 14.9 months as compared with 11.2 months in the placebo group. The secondary endpoint of time to the first symptomatic skeletal event was significantly delayed by radium-223 as compared with placebo (median 15.6 vs. 9.8 months; hazard ratio, 0.66; 95% CI, 0.52-0.83; P < 0.001). The tolerability of radium-223, and the demonstrated OS benefit has made this therapy an attractive option in both pre and post-docetaxel settings. However, this therapy is active against bone metastases only and patients with significant visceral disease were excluded from the pivotal trial. In addition, the extent of pain control and magnitude of alleviation of other symptoms (besides skeletal events) have not been formally evaluated.
Concurrent palliative and supportive therapy plays a critical role in optimizing systemic therapy in patients with metastatic prostate cancer. Antiemetics and premedications to avert hypersensitivity reactions are some of the key components of care during administration of either docetaxel or cabazitaxel. Close monitoring for cytopenias, dose modifications as necessary for neuropathy related to docetaxel, and for diarrhea and cytopenias related to cabazitaxel, should be an integral part of the chemotherapy care. Primary growth factor prophylaxis is strongly recommended for cabazitaxel chemotherapy and secondary prophylaxis should be considered for either chemotherapy agent if febrile neutropenia occurs. Monitoring for cardiac function, adrenal insufficiency, fluid retention, hypertension and hypokalemia is important in conjunction with abiraterone therapy. Prednisone supplementation is required in combination with abiraterone to alleviate the mineralocorticoid excess and the subsequent toxicities that are related to it. Enzalutamide therapy resulted in a 0.9% risk of seizures. Patients with history of seizures, or any risk factors for seizures, were excluded from enzalutamide therapy. Physician, patient and family awareness and education regarding toxicities enables prompt attention to adverse events and better outcomes with therapy.
Novel agents with promising efficacy in castrate-resistant prostate cancer
Cabozantinib has dual VEGF and c-met inhibition properties that uniquely fit the current need to delay development of resistance and maintain VEGF inhibition in advanced prostate cancer. The agent demonstrates the unique phenomenon of effecting complete responses or normalizations of bone scans in metastatic prostate cancer. In a phase II randomized discontinuation study [24] , cabozantinib demonstrated broad clinical activity in men with CRPC. An increase in PFS was observed in the cabozantinib arm compared with placebo (median PFS 23.9 vs. 5.9 weeks) with a bone scan response seen in 67% of the patients treated.
TAK-700/orteronel is an oral, nonsteroidal, selective inhibitor of 1720-lyase, a key enzyme in the production of steroidal hormones (http://www. takeda.com/news/2013/20130726_5894.html). A phase III study (C21005) of orteronel plus prednisone compared with placebo plus prednisone in patients with metastatic CRPC following chemotherapy was halted after a prespecified interim analysis indicated that orteronel plus prednisone was not likely to meet the primary endpoint of improved OS when compared with the control arm (HR 0.894, P ¼ 0.226) [25] . The interim analysis did show an advantage for orteronel plus prednisone for the secondary endpoint of radiographic PFS and no toxicity concerns were seen (HR 0.755, P ¼ 0.00029). It is likely that the OS benefit noted was blunted because of cross-over of the placebo patients to abiraterone therapy, which has a similar mechanism of action to enzalutamide therapy, which also affects the androgen-receptor interaction axis, as both these agents had received FDA approval during the trial. Phase III trials are ongoing in hormone-sensitive disease (SWOG 1216) and in chemotherapy-naïve metastatic CRPC (ELM-PC4).
ARN-509 is a competitive androgen receptor inhibitor that is thought to be more potent than enzalutamide [26] . A phase II study showed that ARN-509 has a very high PSA response rate in treatment-naïve CRPC (88%) and it appears to retain activity in abiraterone pretreated mCRPC with a PSA response rate of 29%. No seizures were reported. The agent is being evaluated in the setting of nonmetastatic CRPC in a double blind placebo controlled randomized trial.
PROSTVAC-VF is a PSA targeted vaccine that was evaluated in a randomized blinded phase II study in 125 men with metastatic CRPC. Men with visceral metastases, cancer-related pain requiring narcotics, prior chemotherapy or PSA more than 7 were excluded. The primary end point was PFS, which was similar in the PROSTVAC-VF arm and the placebo arm [27] . However, PROSTVAC-VF patients had improved OS over placebo (25.1 vs. 16.6 months, HR 0.56, P ¼ 0.0061). A phase III trial is ongoing with primary endpoint of OS. Immune checkpoint blockade with CTLA-4 inhibition has also demonstrated preclinical efficacy in prostate cancer. Synergistic activity was observed with the combination of radiation therapy and ipilimumab, a CTLA-4 antibody. A phase I/II study [28] revealed clinical activity, and now a randomized clinical trial has been completed and results are awaited. Clusterin overexpression has been reported to be an important mechanism of chemoresistance in metastatic prostate cancer. OGX-011, an antisense inhibitor of clusterin has demonstrated promising efficacy when added to docetaxel-based chemotherapy. A phase II randomized trial revealed an increase in median OS from 16.9 to 23.8 months with the addition of OGX-011 to docetaxel therapy [29] . Phase III trials of OGX-011 in conjunction with both docetaxel and cabazitaxel are being conducted. Selected novel agents with promising efficacy are summarized in Table 2 [24] [25] [26] [27] [28] [29] . Figure 1 summarizes the treatment algorithm for metastatic prostate cancer based on current available data. Significant strides have been made with clinically relevant impact on the morbidity and mortality of advanced prostate cancer. The last few years have demonstrated a switch from chemotherapy-based regimens to nonchemotherapy options in metastatic CRPC. This has made systemic therapies widely applicable and feasible, as even elderly patients, or those with significant comorbidities, can tolerate the treatments. The interspersing and sequencing of the numerous agents now approved for metastatic CRPC require further study. Development of predictive biomarkers for each of the therapies currently available will reduce costs, enhance outcomes and optimize toxicities.
CONCLUSION

